Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the Americas there are between 4,500 and 6,800 annual cases of severe visceral leishmaniasis, and mortality is estimated to range between 7 and 10%. However, underreporting and subclinical infections mask the real epidemiological importance of visceral leishmaniasis. Control efforts, which have typically focused on insecticide spraying of sand fly vectors and dog culling, have yielded disparate results. Nevertheless, thousands of dogs are sacrificed each year in countries endemic for visceral leishmaniasis. Additionally, current guidelines of leishmaniasis control programs have banned dog treatment with drugs of human use while therapy with other drugs resulted in high rates of relapses. Society requires that control programs take a more humanitarian approach aimed at limiting dog culling. There is an urgent need to promote responsible dog-ownership and support research on: a) novel veterinary therapies, b) low-cost molecular diagnosis of canine visceral leishmaniasis, and c) determination of dog infectivity threshold for proper reservoir management.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalBiomedica
Volume34
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Visceral Leishmaniasis
Latin America
Dogs
Reservoir management
Spraying
Insecticides
Pharmaceutical Preparations
Masks
Sand
Psychodidae
Asymptomatic Infections
Leishmaniasis
Ownership
Canidae
Costs
Guidelines
Costs and Cost Analysis
Recurrence
Mortality
Therapeutics

Keywords

  • Dogs
  • Latin america
  • Leishmania infantum
  • Leishmaniasis
  • Therapy
  • Visceral/prevention&control

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America. / Travi, Bruno.

In: Biomedica, Vol. 34, No. 1, 2014, p. 7-12.

Research output: Contribution to journalArticle

@article{f7cecb788aab4ddc9d8c8afb1eb7f681,
title = "Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America",
abstract = "In the Americas there are between 4,500 and 6,800 annual cases of severe visceral leishmaniasis, and mortality is estimated to range between 7 and 10{\%}. However, underreporting and subclinical infections mask the real epidemiological importance of visceral leishmaniasis. Control efforts, which have typically focused on insecticide spraying of sand fly vectors and dog culling, have yielded disparate results. Nevertheless, thousands of dogs are sacrificed each year in countries endemic for visceral leishmaniasis. Additionally, current guidelines of leishmaniasis control programs have banned dog treatment with drugs of human use while therapy with other drugs resulted in high rates of relapses. Society requires that control programs take a more humanitarian approach aimed at limiting dog culling. There is an urgent need to promote responsible dog-ownership and support research on: a) novel veterinary therapies, b) low-cost molecular diagnosis of canine visceral leishmaniasis, and c) determination of dog infectivity threshold for proper reservoir management.",
keywords = "Dogs, Latin america, Leishmania infantum, Leishmaniasis, Therapy, Visceral/prevention&control",
author = "Bruno Travi",
year = "2014",
doi = "10.7705/biomedica.v34i1.2153",
language = "English (US)",
volume = "34",
pages = "7--12",
journal = "Biomedica",
issn = "0120-4157",
publisher = "Instituto Nacional de Salud",
number = "1",

}

TY - JOUR

T1 - Ethical and epidemiological dilemmas in the treatment of dogs for visceral leishmaniasis in Latin America

AU - Travi, Bruno

PY - 2014

Y1 - 2014

N2 - In the Americas there are between 4,500 and 6,800 annual cases of severe visceral leishmaniasis, and mortality is estimated to range between 7 and 10%. However, underreporting and subclinical infections mask the real epidemiological importance of visceral leishmaniasis. Control efforts, which have typically focused on insecticide spraying of sand fly vectors and dog culling, have yielded disparate results. Nevertheless, thousands of dogs are sacrificed each year in countries endemic for visceral leishmaniasis. Additionally, current guidelines of leishmaniasis control programs have banned dog treatment with drugs of human use while therapy with other drugs resulted in high rates of relapses. Society requires that control programs take a more humanitarian approach aimed at limiting dog culling. There is an urgent need to promote responsible dog-ownership and support research on: a) novel veterinary therapies, b) low-cost molecular diagnosis of canine visceral leishmaniasis, and c) determination of dog infectivity threshold for proper reservoir management.

AB - In the Americas there are between 4,500 and 6,800 annual cases of severe visceral leishmaniasis, and mortality is estimated to range between 7 and 10%. However, underreporting and subclinical infections mask the real epidemiological importance of visceral leishmaniasis. Control efforts, which have typically focused on insecticide spraying of sand fly vectors and dog culling, have yielded disparate results. Nevertheless, thousands of dogs are sacrificed each year in countries endemic for visceral leishmaniasis. Additionally, current guidelines of leishmaniasis control programs have banned dog treatment with drugs of human use while therapy with other drugs resulted in high rates of relapses. Society requires that control programs take a more humanitarian approach aimed at limiting dog culling. There is an urgent need to promote responsible dog-ownership and support research on: a) novel veterinary therapies, b) low-cost molecular diagnosis of canine visceral leishmaniasis, and c) determination of dog infectivity threshold for proper reservoir management.

KW - Dogs

KW - Latin america

KW - Leishmania infantum

KW - Leishmaniasis

KW - Therapy

KW - Visceral/prevention&control

UR - http://www.scopus.com/inward/record.url?scp=84901382119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901382119&partnerID=8YFLogxK

U2 - 10.7705/biomedica.v34i1.2153

DO - 10.7705/biomedica.v34i1.2153

M3 - Article

VL - 34

SP - 7

EP - 12

JO - Biomedica

JF - Biomedica

SN - 0120-4157

IS - 1

ER -